Difference between revisions of "Uy GL, et al. Blood (2012) cited as Ref 630 in DOI: 10.1038/s41392-020-0110-5 (Q9893)"
Jump to navigation
Jump to search
(Created claim: title (P93): A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 3917-3924, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 3917-3924 | ||
| Property / Page(s): 3917-3924 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Uy GL, et al. Blood (2012) cited as Ref 630 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Uy GL
0 references
2012
0 references
Blood
0 references
119
0 references
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (English)
0 references
3917-3924
0 references
